ORKA Reports $0 Revenue, $0 EPS, +0% YoY; ORKA-001 Achieves 63.5% PASI 100 at Week 16; Conference Call Today 8:00 a.m. ET; Phase 1 PK/PD Supports Annual Dosing; Longer-Term Data Expected 2H 2026
Oruka Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $55.01
-10% in 3d after detection
Post-detection moves
1h
—
1d
-3.1%
3d
-10%
7d
-8.6%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS